Post by Boehringer Ingelheim

#NEWS: Small cell lung cancer (SCLC) progresses rapidly and for people facing this cancer prognosis is poor. Current treatment options often offer only limited responses, resulting in significant disease and treatment burden and underscoring the urgent need for innovative approaches. That’s why we are collaborating with BioNTech SE to evaluate whether a novel investigational combination approach in SCLC has the potential to deliver more durable benefit for patients. The Phase Ib/II study will explore the combination of T‑cell engagement with checkpoint inhibition and vascular growth blockade, aiming to assess complementary immuno‑oncology mechanisms.   Learn more: https://lnkd.in/dYc6y_GD   #CancerResearch #Immunotherapy #SmallCellLungCancer